Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $5 is 108.33% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 5.25||$ 8.59|
|Low:||$ 4.90||$ 2.40|
Company Description (as filed with the SEC)
We are a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Leveraging our next-generation adeno-associated virus ("AAV")-based directed evolution platform, we generate gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development and in-house manufacturing expertise, specifically in process development, assay development, and current Good Manufacturing Practices ("cGMP") quality control. Our leadership team has significant drug development and gene therapy expertise. We are advancing our robust pipeline of gene therapy product candidates designed to treat rare diseases, alpha-1 antitrypsin ("A1AT") deficiency and hereditary angioedema ("HAE"), as well as wet age-related macular degeneration ("wAMD"). Our pipeline of lead and partnered gene therapy programs is shown below. ... More ...
Nasdaq Official Price
Jul. 20, 2018
Jul. 20, 2018